Intelligence Feed event · Policy · 2026-09-13

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Question

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Direct answer

    The US Food and Drug Administration has granted marketing approval for Scholar Rock's Isembyld (apitegromab-mstn). This makes it the first muscle-directed therapy authorized for patients with spinal muscular atrophy, functioning complementary to existing SMN-upregulating treatments. Approval was granted following Phase 3 SAPPHIRE study outcomes, which demonstrated statistically significant and clinically meaningful gains in patient motor function scores.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy”, revision 1, evidence through 2026-09-13. https://marketontology.com/market-events/2026-09-13/fda-approves-scholar-rock-s-isembyld-for-spinal-muscular-atrophy-2fcd56

    POLICY
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    The US Food and Drug Administration has granted marketing approval for Scholar Rock's Isembyld (apitegromab-mstn). This makes it the first muscle-directed therapy authorized for patients with spinal muscular atrophy, functioning complementary to existing SMN-upregulating treatments. Approval was granted following Phase 3 SAPPHIRE study outcomes, which demonstrated statistically significant and clinically meaningful gains in patient motor function scores.
    SRRK
    Impact
    74
    SEP 13
    SIG
    95%
    SRRK
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    The US Food and Drug Administration has granted marketing approval for Scholar Rock's Isembyld (apitegromab-mstn). This makes it the first muscle-directed therapy authorized for patients with spinal muscular atrophy, functioning complementary to existing SMN-upregulating treatments. Approval was granted following Phase 3 SAPPHIRE study outcomes, which demonstrated statistically significant and clinically meaningful gains in patient motor function scores.
    → Regulatory commercialization approval establishes a new market category, unlocking therapeutic sales and product revenues for SRRK.
    Impact
    The US Food and Drug Administration has granted marketing approval for Scholar Rock's Isembyld (apitegromab-mstn). This makes it the first muscle-directed therapy authorized for patients with spinal muscular atrophy, functioning complementary to existing SMN-upregulating treatments. Approval was granted following Phase 3 SAPPHIRE study outcomes, which demonstrated statistically significant and clinically meaningful gains in patient motor function scores.
    Affected
    SRRK
    Transmission
    Regulatory commercialization approval establishes a new market category, unlocking therapeutic sales and product revenues for SRRK.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SRRKcommercial drug approval unlocking market entry and revenue generationUp1-5dFDA approved Isembyld (apitegromab-mstn) for SMA.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month